Aug. 2 at 10:10 AM
$TEVA Grok says regarding effect of tariffs on Trva:
Teva Pharmaceutical Industries is minimally affected by U.S. tariffs due to its strong domestic manufacturing presence and limited reliance on imports from high-tariff regions. Over 50% of Teva’s U.S. products, including its lead drug Austedo, are manufactured locally across eight U.S. production sites, reducing exposure to tariffs. The company has very limited sourcing from China and India. Teva’s CEOand CFO have stated that existing tariffs are already factored into their 2025 financial guidance, and they expect any potential tariff impacts to be immaterial due to their robust U.S. supply chain and inventory management. However, there is some ambiguity regarding the specifics of proposed tariffs, particularly from the Trump administration, and certain generic drugs may be exempt, though details remain unclear. Teva’s strategic focus on local production and contingency planning further mitigates potential tariff-related disruptions
